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Abstract 
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder characterized by the degeneration of lower 
motor neurons (MNs) in the spinal cord and brain stem, which results in relentless muscle weakness and wasting, leading to 
premature death due to respiratory complications. The identification of the specific mutations in the survival motor neuron 1 
(SMN1) gene that causes SMA has led to the development of experimental therapeutic strategies to increase SMN protein 
expression, including antisense oligonucleotides, small molecules, and gene therapy, which have so far shown promising results. 
The timing of therapeutic intervention is crucial since most of the degeneration in MNs occurs in the first months of life in patients 
with SMA type 1, which is the most severe and common form of SMA. Nevertheless, a precise temporal window for therapeutic 
intervention has not yet been identified. Evidence from in vivo studies in mice and large animals suggested that early therapeutic 
intervention for SMA correlated with better motor performance, longer survival, and, occasionally, rescue of the pathological 
phenotype. Indeed, the need to compensate for the loss of SMN protein function seemed to diminish during adulthood (even 
though repair ability after nerve injury remained impaired), suggesting the possibility of tapering the therapy administration late 
in the disease course. Moreover, recent clinical trials on children afflicted with SMA type 1 have shown a more rapid achievement 
of motor milestones and diminished disease severity when therapy was administered at an early age and earlier in the disease 
course. Finally, these results highlight the importance of newborn screening for SMA to facilitate early diagnosis and present the 
patient with available treatments while they are still in the presymptomatic stage. 
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Introduction 
Spinal muscular atrophy (SMA) is a hereditary and progressive 
neuromuscular disease that is characterized by proximal-distal 
muscular weakness and atrophy, which results from the degener- 
ation of lower motor neurons (MNs) in the ventral horns of the 
spinal cord and in lower brainstem nuclei [1, 2]. SMA is the most 
common autosomal recessive disease after cystic fibrosis and is 
the leading genetic cause of death in infancy [3–5]. The disease 
incidence is about 1 in 10,000 live births, whereas the carrier 
status incidence is 1 in 40 to 60 depending on the ethnicity [6–8]. 
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In 98% of cases, the disease is caused by a homozygous 
mutation, deletion, or rearrangement in the survival motor neu- 
ron 1  (SMN1)  gene  on  chromosome  5 (SMA5q, OMIM 
#253300), which encodes the SMN protein. Only the human 
genome, and no other species, encodes a highly homologous 
copy of SMN1 called SMN2; SMN2 differs from SMN1 by a few 
nucleotides, of which the most critical is a C to T transition in 
exon 7 that causes the skipping of this exon in > 90% of SMN2 
transcripts [6]. For this reason, SMN2 mainly produces a trun- 
cated protein (Δ7), without exon 7, much of which is unstable 
and rapidly degraded [9]; moreover, SMN2 expression consti- 
tutes only 10% of the full-length fully functional SMN protein 
[10] and thus partially compensates for the loss of SMN1.
In SMA patients, SMN2 is the major modulator of the dis-
ease phenotype, and the number of SMN2 copies inversely 
correlates with the severity of the phenotype. SMA types are 
classified by the higher motor milestones achieved such that 
untreated SMA type 1 patients never acquire the ability to sit 
and stand, and SMA type 2 patients are able to sit but cannot 
  
 
walk; however, SMA type 3 manifests after ambulation has 
been acquired. Because SMN protein is essential for viability, 
all SMA patients have at least one copy of SMN2. The SMN 
protein seems to play an important role in spliceosomal 
snRNP biogenesis and in mRNA splicing, but the precise 
mechanisms by which defects in this ubiquitously expressed 
protein selectively affect motor neuron viability remain large- 
ly unclear [11]. 
In the last 20 years, there have been increasing efforts to 
develop a therapeutic strategy for SMA. In particular, these 
efforts focused on increasing the SMN protein level by deliv- 
ering a wild-type copy of SMN1 to patients through either 
gene therapy or by modulating the transcription of the SMN2 
gene using oligonucleotides or small molecules. 
SMA is considered an optimal candidate disease for gene 
therapy for several reasons. First, without treatment, SMA 
would be a fatal disease. Second, the specific genetic target 
(SMN1) and cell population (lower MNs) affected in SMA 
are known. Third, toxicity from gene therapy would be minimal 
because SMN overexpression in tissues other than lower MNs 
is well tolerated and the presence of SMN2 reduces the risk of 
an autoimmune response. Fourth, preclinical studies can be 
developed owing to robust animal models for SMA and SMN 
cDNA length that are appropriate for gene therapy vectors. 
Finally, since there is an inverse correlation between the number 
of SMN2 copies and the severity of the disorder, strategies 
aimed at increasing SMN protein levels by modulating SMN2 
splicing can be used. The results obtained from this study led to 
clinical trials that are currently ongoing and rapidly ap- 
proaching the approval of the first therapy for SMA based on 
the use of antisense oligonucleotides (Nusinersen, Spinraza). 
The SMN protein has been studied in different animal 
models to define its specific role and the specific timeframe 
that it intervenes in MN development. The wide variability of 
the SMA phenotypes, the age of onset, which in 60% of cases 
occurs in the first few months of life, and the fact that the vast 
majority of treatments seem to prevent/stop disease rather than 
reverse MN death emphasize the importance of identifying the 
best therapeutic window to intervene in SMA. 
 
Therapeutic Window in Humans Based on the Natural 
History of the Disease 
 
In the first 6 months of life, infants with SMA type 1 
(Werdnig–Hoffmann disease) show symptoms of proximal 
muscle weakness that affects the lower limbs more than the 
upper limbs [2]. 
The average age of death or the age when a patient starts to 
need more than 16 h per day of ventilation in SMA type 1 
patients is 13.5 months [10]. A recent study of natural history 
of SMA showed that the median survival time for SMA in- 
fants excluding participants with more than two copies of 
SMN2 was 8 months [12]. 
The motor function decline, as determined by the 
Children’s Hospital of Philadelphia Infant Test of 
Neuromuscular Disorders (CHOP-INTEND) scale in untreat- 
ed children, showed a loss of 1.27 points per year. The highest 
score of the scale is 64 points; at disease onset, the mean score 
of SMA patients is 25, and the maximum score is up to 40 
points [10]. 
It has been demonstrated that infants with SMA type 1 
undergo a rapid loss of motor units in the first 3 months of 
life, with more than 95% of motor units lost within 6 months 
of age [12, 13]. Denervation was determined using electro- 
physiological tests for the motor unit number estimation 
(MUNE) and maximum compound motor action potential 
amplitude (CMAP) studies [13]. SMA type 1 infants showed 
a uniformly low CMAP at the time of diagnosis, while in 
presymptomatic infants, the CMAP value was higher and de- 
creased as patients became symptomatic [13]. In a case report 
described by Finkel, the CMAP value of an SMA type 1 
patient who was identified while presymptomatic exhibited 
the same pattern of decline. The decline in the INTEND motor 
scale followed a parallel course to the decline in the CMAP, 
from presymptomatic at day 5 to moderately affected on day 
34. Further deterioration at day 63, when the patient was fully 
symptomatic, was mainly observed in the patient’s bulbar 
muscles and breathing functions, with motor function and 
CMAP values remaining at the nadir. The patient died at 
81 days, and no autopsy was performed [10]. 
The extent of MN loss has been reported as profound   
in most postnatal autopsy studies. Soler-Botija et al. de- 
scribed an approximately 50–60% loss of MNs in one 
SMA newborn and four SMA infants aged 4–9 months     
of age [14]; moreover, Simic et al. described that approx- 
imately 73% of MNs were lost in five genetically con- 
firmed SMA type I cases aged 5–22 months [15]. Simic    
et al. reported that 0.2–6.4% of the remaining MNs 
showed the activation of apoptosis (TUNEL positivity), 
while other studies did not report signs of apoptosis [14, 
16]. Since apoptosis can be an ongoing, intermittent, and 
relatively rapid process, it may be very difficult to detect 
the occurrence of apoptosis at a single stage in an autoptic 
spinal cord report. It is also possible that apoptosis is more 
evident during the early phases of the disease [16]   or that 
other mechanisms such as necroptosis occur. 
To obtain beneficial results in treating severe SMA type 1, 
the therapeutic window is narrow; based on neurophysiolog- 
ical and autoptic data, the period within the first 3 months 
appears to be permissive to have an impact on the disease 
phenotype, whereas the period between 3 and 6 months ap- 
pears to be suboptimal for therapeutic intervention. However, 
therapies should be started well before the loss/damage of 
MNs, and the current results of the therapeutic trials suggest 
that the therapy should be administered prior to a month, and 
when is possible within a week after birth. 
 
 
 
 
Regarding the natural history of SMA types 2 and 3 [17], 
the motor functions tested with the Expanded Hammersmith 
Functional Motor Scale (HFMSE) from baseline presented a 
stable trend in the first year and a decline rate of 1.71 points in 
3 years (having type 3a resulted in a meaningful clinical dif- 
ference). The ability to walk at 20 years of age for patients 
with SMA type 3 was 44% for SMA type 3a patients (onset < 
3 years) and 89% for SMA type 3b patients (onset > 3 years) 
[17]. The therapeutic windows, based on neurophysiological 
and postmortem data, for SMA type 2 and 3 patients were less 
clearly defined [2]. In fact, studies including the correlation 
between presymptomatic and postsymptomatic electrophysi- 
ological data and postmortem data in SMA type 2 and 3 pa- 
tients are limited [2]. 
To optimize the identification and treatment of the disease, 
newborn screening for SMA will allow for the early detection 
of candidates for approved therapy and for their enrollment in 
clinical trials. The therapeutic window determined in the clin- 
ical trial is discussed more extensively later in this manuscript. 
Furthermore, early diagnosis would accelerate the planning 
and the beginning of medical care for nutrition, respiratory, 
and physical therapy, thus preventing and curbing complica- 
tions of the disease. The implementation of timely treatment 
would also reduce the cost of medical care. Moreover, new- 
born screening would prompt parents to be more prepared for 
genetic counseling in anticipation of a second child. 
 
Therapeutic Window in a Transgenic Model 
with Conditional Expression of SMN 
 
To discover and better understand the time-dependent role of 
SMN during MN development and maturation, different SMA 
animal models were generated (Fig. 1). 
In the zebrafish (Danio rerio) SMA model, the absence of 
SMN compromised dendritic and axonal growth [18]. The 
requirement for SMN was greatest during embryogenesis, 
when MNs establish connections with their respective targets 
[18]. The period within 36 h postfertilization corresponds to 
the development of the central nervous system and other or- 
gans of the embryo, and no benefit was observed when SMN 
protein was added after this period (Fig. 1). It is important to 
notice that while zebrafish show developmental abnormalities 
of motor neurons, this finding does not appear to be replicated 
in the mouse models [19, 20]. 
Le et al. developed an SMA mouse model in which the 
SMN2 expression was inducible only by the administration 
of doxycycline; in this study, the protein expression was in- 
duced at different time points. Le et al. found that in the em- 
bryonic or early postnatal period (0 and 1 postnatal day 
(PND)), the induction of SMN2 expression resulted in a sub- 
stantial rescue of SMA mice (survival over 200 days), while 
postnatal induction in later periods resulted in reduced rescue. 
The critical window of intervention was between birth and 
PND4 (Fig. 1). Delaying SMN induction by only 1 day, with 
SMN expression detected at PND5, diminished the benefits in 
terms of the survival duration and activity of SMA mice. 
Furthermore, the long-term requirement of SMN was in- 
vestigated by withdrawal of doxycycline at PND28 in rescued 
mice. One month after the removal of doxycycline, the mice 
mostly demonstrated a rapid decline in motor functions and 
died at 1 month of age, despite the observation that there were 
no differences in neuromuscular transmission compared to 
heterozygous controls. This result suggested that the function 
of the neuromuscular junction (NMJ) was not dependent on 
the expression of SMN in adult mice and that two copies of 
SMN2 are sufficient for survival in adults but not during the 
critical postnatal period [21]. 
An independent study investigated the effect of inducing 
SMN expression in SMA mice using a tamoxifen-inducible 
CRE-responsive allele [22]. The earlier the protein was re- 
stored, the fewer abnormalities of NMJs were observed, and 
consequently, the more effective the therapeutic intervention 
was deemed to be; these results revealed that there was a 
narrow temporal sensitivity of transgenic mice MNs placed 
between PND4 and PND8 (Fig. 1). This work confirmed that 
reactivation of SMN protein after disease onset could halt the 
 
Fig. 1 Schematic representation 
of the therapeutic window 
identified in animal models of 
SMA type 1. Along the lifespan 
of the animals, the colors 
represent the period when the 
therapy can take effect: pink is the 
period when the therapy can be 
most effective, while orange and 
yellow are the age ranges for 
which the administration of the 
therapy has progressively less 
efficacy. h hours after fertilization, 
B birth, PND postnatal day 
  
 
progression of SMA pathology, and thus, earlier intervention 
(i.e., prenatal) was required to reverse the deficit in overall 
growth. 
Nevertheless, it is critical to intervene in SMA before MN 
loss has occurred because SMN expression cannot be effec- 
tive once neurons have died. 
Since direct SMN restoration represents a therapeutic 
option in SMA, it seems important to define, in addition   
to than the optimal window of opportunity for therapeutic 
intervention, whether the requirement of the protein chang- 
es with time and/or is dependent on other factors. A line of 
tamoxifen-responsive SMN2 transgenic mice was used to 
investigate this purpose. Neonatal depletion of SMN 
caused the development of a severe and fatal SMA pheno- 
type. Similar results were observed when SMN was deplet- 
ed at different time points between PND4 and PND12, 
such that mice exhibited rapid loss of body weight and 
impaired motor abilities that resulted in muscle paralysis 
[23]. In contrast, administration of tamoxifen and conse- 
quent SMN depletion at PND15 lessened the severity of 
the disease, as if a reduced quantity of the protein was 
required for normal neuromuscular function in adult age. 
The transition from an SMN-dependent state to a state of 
relative SMN insensitivity was identified as a 3-day win- 
dow between approximately P12 and P15, which reflected 
the period of transformation of NMJs into mature synap- 
ses. An insufficient amount of SMN protein impaired long- 
term maintenance of MNs and muscles, resulting in the 
eventual alteration of NMJ and muscle fiber pathology. 
Indeed, these structures need to be replaced periodically 
during adulthood as a consequence of the normal process 
of aging, injury, or disease. Further experiments demon- 
strated that inducing NMJ turnover by injuring the nerve 
cells aroused the requirement for high levels of SMN pro- 
tein. This was also true for muscle regeneration, highlight- 
ing the critical role of SMN in the regulation and mainte- 
nance of the neuromuscular system. Experiments conduct- 
ed in SMA mice showed a correlation between the timing 
of SMN restoration and the development of plaque-like 
AChR (acetylcholine receptor) clusters [24]. This result 
indicated an important role of the SMN protein in the 
maintenance of MNs and in the formation of adult neuro- 
muscular synapses. 
The NMJ maturation and regeneration in response to 
internal or external factors defined the temporal require- 
ment for the SMN protein. If so, a therapeutic SMN- 
enhancing agent in human patients could be administered 
in an early postnatal period, then tapered during adulthood 
once the neuromuscular system has fully developed and 
then reintroduced as needed in response to injuries or ag- 
ing. However, this can be true for drugs modulating SMN 
gene activation and alternate splicing or stabilizing SMN 
protein (e.g., small molecules, antisense oligonucleotides 
(ASOs), and other drugs), nor for gene replacement strate- 
gy (i.e., gene therapy). 
The neuronal aspect and the phenotype of the animals were 
influenced and corrected after cellular pathology evidence and 
symptom onset. These results extended the therapeutic win- 
dow, and provided the rationale to treat young patients, also in 
postsymptomatic period, by modulating the expression of the 
SMN2 gene or delivering the SMN1 gene [22]. 
Nevertheless, it should be noted that SMA mouse models 
differ from human patients since they show peripheral organ 
deficiency and malfunction (e.g., significant reduction in 
spleen size, intestinal and metabolic abnormalities) compared 
to SMA patients. Such abnormalities are lesser or not at all 
described in human beings, who developed most of all a neu- 
rologic phenotype. Therefore, MN involvement seems to be 
stronger for human patients than mouse models, suggesting a 
greater SMN sensitivity also in adult age. 
 
Milder Models of Disease 
 
Studies describing the severe phenotype mouse models of 
SMA, with a median survival of 12–14 days after birth, rep- 
resent the principal source of knowledge about the temporal 
requirement for SMN in mammals. Nevertheless, the rapid 
disease progression of these mice, combined with some phe- 
notypes, such as cardiac defects, limited their use in testing the 
efficacy of therapeutic interventions. Milder models of SMA 
have been generated by Bogdanik et al. in order to assess the 
temporal window for therapeutic SMN restoration in SMA 
type 2/3 patients [25]. The BBurgheron^ mouse exhibited an 
intermediate lifespan (mean survival of 89 days), delayed 
structural maturation of NMJs, and specific electrophysiolog- 
ical findings (reduction of CMAP and MUNE). Systemic ad- 
ministration of ASOs has been found to restore neurological 
phenotype and to extend mouse survival. In severe SMA 
mice, SMN restoration was efficacious within the early post- 
natal days, and in milder models, positive effect of interven- 
tion was also obtained after the onset of neurological 
symptoms. 
Zhou et al. generated an intermediate SMA model by ad- 
ministering a low-dose morpholino antisense oligomer 
PMO25 to neonatal mice from a Taiwanese model of severe 
SMA [26]. PMO25 was administered at different time points 
and with different modalities: periodic systemic administra- 
tion of low dose of PMO25 (at 2-week intervals) showed 
longer term therapeutic benefits than single low-dose 
(PDN5) and single bolus high-dose injection at PND0 (with 
better results when the bolus was administered earlier in the 
disease course). 
Another recent study succeeded in obtaining a milder SMA 
phenotype through administration of a suboptimal dose of 
SMN2 splicing modifier in a Δ7 mouse model [27]. These 
mice survived longer (reaching adult age) than untreated mice 
 
 
 
 
and showed adult SMA-like pathology, i.e., synaptic defects 
in NMJs and muscle atrophy. After manifestations of symp- 
toms, the administration of an increased dose of the splicing 
modifier ameliorated the synaptic alterations, and the admin- 
istration of a myostatin inhibitor reduced atrophy of muscle 
fibers in Δ7 mice that obtained a suboptimal dose. Thus, this 
work provides a murine model of mild SMA pathology, re- 
sembling the phenotype of adolescent and adult patients. In 
addition, these experiments suggested that the window of in- 
tervention in SMA types 3 and 4 seemed to be linked to age of 
onset of the disease and might be broader than types 1 and 2. 
Thus, SMN-targeted therapies administered after disease on- 
set may only have a limited capacity to improve disease phe- 
notype. In contrast, rescue of SMN levels in a milder SMA 
mouse model significantly ameliorated motor abilities, 
pointing out a potential difference related to the timing and 
nature of the therapeutic window in severe versus mild forms 
of SMA. 
 
Therapeutic Window in SMA Mice Preclinical 
Therapeutic Experiments 
 
Since the loss of MNs and neuromuscular symptoms in SMA 
are due to a genetic defect in the gene coding for SMN protein, 
one of the most promising therapeutic interventions is the 
delivery of the wild-type allele to affected neurons. Several 
studies have been performed to address SMN gene delivery to 
target cells through viral vectors; in these studies, bypassing 
the blood–brain barrier (BBB) to reach the central nervous 
system was one of the most challenging issues. During devel- 
opment, the permeability of the BBB progressively decreases 
due to the growth of the capillary endothelial cells. 
Furthermore, it is noteworthy that, in SMA pathogenesis, the 
younger the subject is, the healthier the MNs are. It is therefore 
crucial to identify the optimal temporal window in order to 
enable the vector to reach the correct target and the majority of 
cells. 
The intravenous administration of adeno-associated virus 9 
(AAV9) was indeed tested in mice at different ages [28]. In 
neonatal mice, systemic delivery of the AAV9-GFP fluores- 
cent reporter resulted in a robust expression of GFP in the 
heart, skeletal muscles, and spinal cord with transduction in 
the dorsal root ganglia, in the MNs of the ventral region (56 
and 61% of MNs were positive for GFP 10 and 21 days after 
injection, respectively), and in astrocytes. Neurons and astro- 
cytes in the brain were also positive for GFP expression. 
When the same vector was administered to older mice, histo- 
chemical analysis revealed a loss of transduction in the dorsal 
root ganglia and a marked decrease in the GFP-positive MNs 
in the ventral part of the spinal cord. However, GFP-positive 
astrocytes were found at all levels of the spinal cord, and 
selective neuronal expression in the hippocampus and dentate 
gyrus was also observed. 
These data demonstrated that there is a crucial period dur- 
ing which the cells of the dorsal root ganglia and the lower 
MNs can been reached from the circulatory system. The pre- 
dominant astrocyte transduction in adults suggested that the 
viral construct escaped the brain vasculature. Gray et al. found 
that the transduction of GFP throughout the brain and spinal 
cord was dose-related with neurons outnumbering astrocytes 
in the hippocampus (2:1) and striatum (1.9:1) but not the cor- 
tex (1:1). Structures outside of the BBB showed higher overall 
transduction. AAV9 transduced both neurons and astrocytes. 
Biodistribution of GFP was also dose related in the kidneys, 
while in the other tissues (liver, spleen, lung, and skeletal 
muscle), there was a possible saturation of transduction capa- 
bility of AAV9 at a medium or high dose [23]. The following 
step was to test the injection of self-complementary (sc) AAV9 
carrying the full-length SMN cDNA gene in the facial vein of 
1-day-old SMA mice. 
The treated mice exhibited an improvement in the motor 
functions, were larger in size, and had higher body weight 
compared to untreated mice. The lifespan increased to at least 
250 days [29]. Based on this study, scAAV9-SMN was 
injected at different time points. In mice treated at P2, western 
blot analysis showed elevated SMN expression in the brain, 
spinal cord, and muscles, despite not reaching the same level 
of expression as in wild-type mice. Interestingly, delaying 
treatment at P5 determined the occurrence of partial rescue 
of the disease with a reduced lifespan. Finally, injection at 
P10 had little or no effect on reverting the pathological phe- 
notype, suggesting once again the importance of early treat- 
ment to achieve the maximal benefit [29] (Fig. 1). Passini et al. 
investigated the distribution of the SMN transduction accord- 
ing to different amounts of sAAV9-SMN delivered into the 
CNS (through cerebral lateral ventricles and lumbar spinal 
cord) of SMA mice at 1 postnatal day. They found that the 
SMN levels correlated with the doses, and the cells expressing 
the protein were mostly MNs localized to the lumbar region of 
the spinal cord. The percentage of positive MNs decreased in 
the regions that were more distally positioned from lumbar 
injection site. A greater number of positive MNs were found 
in the lumbar, thoracic, and cervical regions of mice treated 
with higher dosages of SMN. It was also observed that the 
average lifespan increased according to the dose used, and the 
mice receiving the highest dosages showed consistent weight 
gain [30]. 
 
AAV9 Administration Testing in Large Animals 
 
Since CNS development is different in mice and primates, the 
timing and efficiency of MN transduction was investigated 
through scAAV9 administration in non-human primates. As 
there is no primate model of disease, the vector has been 
labeled with the GFP. ScAAV9-GFP was intravenously 
injected into a healthy male cynomolgus macaque on P1. 
  
 
After 25 days, GFP-positive cells were detected in dorsal root 
ganglia and MNs of the entire neuraxis, demonstrating the 
ability of the vector to cross the BBB in young non-human 
primates [29]. The transgene expression was then explored in 
non-human primates at different time points from birth 
through 3 years of age [31]. The expression was similar to 
that found in rodents. In all monkeys treated through intravas- 
cular delivery at 1, 30, and 90 postnatal days, the GFP posi- 
tivity was seen primarily in neurons, especially in large MNs 
of ventral horn, and in some glial cells scattered throughout 
the spinal cord. Conversely, in the brain, microglia and astro- 
cytes were the most prominent cell types targeted. In addition, 
GFP-expressing cells were seen in all cortical regions, lateral 
geniculate, midbrain, pons and medulla, thalamus, and puta- 
men. The intravascular delivery of the vector in a 3-year-old 
macaque determined a widespread GFP expression in the 
brain, with cortical and pontine regions having the highest 
prevalence of transduced cells. Systemic gene delivery also 
targeted multiple peripheral organs (skeletal muscles, liver, 
medulla, spleen, testes, lungs, and kidney) except for the heart, 
where the transduction was not efficient [31]. 
In contrast with experiments in mice, the finding that gene 
delivery in a young non-human primate (3 years old) can 
preserve SMN gene expression in not only glia or astrocytes 
but also in MNs could suggest that this approach is applicable 
in humans and is useful for the treatment of SMA types 2 and 
3 [31]. To further increase the potential role of gene therapy, 
direct CSF delivery has been speculated. The intrathecal vec- 
tor delivery resulted in a spread distribution of GFP in the 
brain (from the prefrontal to the occipital cortex and in the 
cerebellum) and the spinal cord similar to systemic delivery; 
however, the number and the intensity of GFP-positive cells 
were greater (10-fold). GFP expression was observed with 
MN transduction of 25–75% in all the segments. The largest 
number of transduced cells was found in the cerebellum. In the 
cortex, GFP positivity was found primarily in pyramidal cells 
and in astrocytes [30, 32–34]. In the animals that received a 
higher dose, the number of positive MNs was higher, and 
transduction was clearly detected also in the glial and neuronal 
cells of the brain cortex and in the Purkinje cells [30]. 
Moreover, the intrathecal administration implied a lower pe- 
riphery distribution of the AAV9 [32]. After viral injection 
through a lumbar puncture in a 1-year-old cynomolgus ma- 
caque, significant GFP transduction in the spinal cord was 
obtained in 29, 53, and 73% of the cervical, thoracic, and 
lumbar regions, respectively. The transduction rate with the 
same dose seemed to improve when subjects were kept in the 
Trendelenburg position for 10 min after vector infusion 
(targeting 55, 62, and 80% of MNs in the three regions of 
the spinal cord, respectively) [35]. The presence in the host 
animals of the antibodies against AAV9 nullified the vector 
and the intended function. In non-human primates that pre- 
sented preexisting AAV9 antibodies, it was reported that no 
vector genome was detected after 24 h [23] when treated in- 
travenously. Conversely, in the monkeys that were treated 
with CSF delivery, no difference was found in the distribution 
between subjects with and without preinjected antibodies 
against the vector [27]. The window of opportunity to target 
spinal MNs in non-human primates encouraged the translation 
to newly diagnosed SMA children. The intrathecal delivery of 
the AAV9-GFP was also tested in 2-month-old pigs, and GFP 
expression in 10–30% of the MNs in the lumbar region oc- 
curred in a dose-dependent manner [36]. Intrathecal and/or 
intracisternal injection of AAV9-GFP in 5-day-old pigs result- 
ed in gene expression in MNs at all levels of the spinal cord, 
and the cerebellar Purkinje cells, nerve fibers, medullar nuclei, 
and scattered cells near the meningeal surface were also easily 
targeted. GFP expression in peripheral tissue was not detected, 
suggesting that the virus was localized mostly in the CNS 
[31]. A large SMA model in the domestic pig was created 
by intrathecal delivery of scAAV9 expressing a shRNA 
targeting pig SMN. A SMA-like phenotype was obtained re- 
ducing the SMN mRNA levels by 73% in MNs postnatally. 
CMAP and MUNE measures presented a correlation with the 
induced phenotype progression in these animals, similar to 
SMA patients. After that, restoration of SMN through 
scAAV9 expressing human SMN administration was tested 
at different time points. When the second treatment was ad- 
ministered at symptoms onset and before CMAP and MUNE 
changes, the phenotype course resulted affected. Also when 
the scAAV9-SMN was delivered after symptoms onset, the 
improvement of the neuropathology and of neurophysiologic 
parameters (CMAP and MUNE) was observed, pointing out 
the possibility to intervene later in the disease process altering 
the progression of symptoms. The improvement of CMAP 
value at later time point it has been hypnotized relates to col- 
lateral re-innervation [37]. 
There are differences in the response of each species to 
gene treatment, in comparison to mouse model where astro- 
cytes have widespread expression of the SMN protein; in pig 
only, rarely glial cells are transduced; furthermore, in the mu- 
rine model, the distribution in the periphery seems to be rele- 
vant for the survival of the animal. These difference are likely 
related to a peculiar species intron structure that influence the 
splicing of genes in relation to the SMN levels, or a different 
sensibility to the human SMN2 regulatory regions [37]. 
 
Therapeutic Window in Clinical Trials 
 
The first approved drug for SMA is Nusinersen (IONIS- 
SMNrx), which is a 2′-O-methoxyethyl phosphorothioate- 
modified antisense drug designed to bind the SMN2 pre- 
mRNA and to promote the inclusion of exon 7. Nusinersen 
was first tested in an open-label, single-ascending dose study 
in patients with symptomatic SMA aged 2–14 years [25]. 
Patients who received the lowest doses (1, 3, or 6 mg) did 
 
 
 
 
not experience a significant change in motor performance, 
while the 9-mg group exhibited a mean increase of 3.1 points 
in the HFMSE scores from baseline at day 85. Moreover, 7 out 
of 10 participants (70%) exhibited an increase of 3 to 7 points. 
The improvement was observed in both SMA type 2 and type 
3 patients, in five out of seven and in two out of three subjects, 
respectively, and across the age range with three children aged 
more than 5 years and four children aged less than 5 years. At 
the long-term follow-up, the mean change in HFMSE score 
from baseline to 9 to 14 months later was 5.8 points. Six of 
eight participants had an increase greater than 3 points. No 
participants in the 9-mg cohort declined in HFMSE score, 
and the range of improvement was 1 to 14 points [38]. 
Patients with SMA type 1 enrolled in the phase 2 open-label 
study of Nusinersen showed important improvement in motor 
function measures, i.e., they acquired the ability to maintain 
the upright position and to walk independently [39]. Included 
patients were aged between 3 weeks and 7 months old, with 
the onset of spinal muscular atrophy symptoms between    
3 weeks and 6 months. A promising clinical response to 
Nusinersen in most, but not all, infants with spinal muscular 
atrophy was observed; however, no comment specifically pro- 
posed that this failure could have been correlated with later 
treatment. Postmortem analysis of patients treated with 
Nusinersen showed drug uptake into MNs throughout the spi- 
nal cord and in neurons and other cell types in the brainstem 
and other brain regions. Moreover, in the spinal cord, SMN2 
mRNA exon 7 inclusion was upregulated and the SMN pro- 
tein level was increased. The interim analyses performed dur- 
ing the phase 3 clinical trial, in which infants with SMA type 1 
(ENDEAR) and children with SMA type 2 (CHERISH) were 
enrolled, showed a good safety profile and the achievement of 
primary endpoints for motor performances (Chiriboga et al. 
2017). In the interim analysis of the ENDEAR study, a signif- 
icantly higher fraction of SMA patients in the Nusinersen 
group than in the control group had a motor milestone re- 
sponse (41 vs. 0%, P < 0.001), and this result prompted to 
an early termination of the trial [40]. In the final analysis, a 
significantly higher proportion of SMA patients in the 
Nusinersen group than in the control group had a motor mile- 
stone response (51 vs.0%). However, of the infants who pre- 
sented motor milestone response, only 8% could sit indepen- 
dently and 1% could stand. By the end-of-trial cutoff date, 
39% of the infants in the Nusinersen group and 68% in the 
control group had died or received permanent assisted venti- 
lation [40]. It is important to notice that the best results of 
ENDEAR study were observed in patients who started treat- 
ment within 13 weeks after the onset of disease [40]. 
Presymptomatic treatment might provide an even great- 
er clinical response; this hypothesis is being examined in 
an ongoing phase 2 study (Nurture, NCT02386553). Data 
presented at a meeting in April 2017 showed that pre- 
symptomatic treatment in SMA type 1 patients (treated 
within 6 weeks of age) is likely more beneficial than in   
the symptomatic cohort tested in the open label and 
ENDEAR studies (Chiriboga et al. 2017). 
Overall, the data obtained with the Nusinsersen trials sug- 
gest that in SMA type 1, treatment within 3 months is associ- 
ated with some motor milestone response, but to have a satis- 
factory clinical meaningful effect treatment within 1 month, or 
even fewer weeks, is probably required. 
The favorable data obtained during the abovementioned 
trials led to the worldwide approval of Nusinersen treatment 
for SMA type 1 patients and for treating SMA types 2 and 3, 
first by the Food and Drug Administration in the USA and 
more recently by the European Medical Agency in Europe. 
Useful information about the therapeutic window in 
humans came from the first gene therapy trial in SMA 
patients. 
Based on extensive preclinical efficacy and safety studies 
in mice and non-human primates, in May 2014, the Phase 1/2 
BGene Transfer Clinical Trial for Spinal Muscular Atrophy 
Type 1^ (clinicaltrials.gov identifier NCT02122952) was 
designed. Patients with SMA type 1 carrying biallelic SMN1 
mutations and two copies of SMN2 were enrolled. Gene 
transfer was obtained via intravenous infusion of a scAAV9 
carrying the SMN gene (AVXS-101) under the control of a 
hybrid CMV enhancer/chicken-β-actin promoter. Depending 
on the cohort, SMA type I patients were 6 or 9 months of age 
and younger (mean age 3.4 months in higher dose cohort). 
Cohort 1 (lower dose 6.7 × 1033 vg/kg) included three sub- 
jects, and cohort 2 (higher dose 2.0 × 109 vg/kg) enrolled 12 
children. 
The published data showed a favorable safety and well- 
tolerated profile of AVXS-101 and, furthermore, the pa- 
tients’ achievement in motor development milestones. In 
both the cohorts, there was an increase in the CHOP- 
INTEND score and in the achievement of motor mile- 
stones. In particular, of the 12 patients in the high dose 
cohort, 11 were able to sit without support, 9 to roll over, 
11 to feed orally and to speak, and 2 to walk independently. 
The study was closed in January 2017, and the data were 
published on November 2017. No new events were report- 
ed, and 15 of 15 patients were event-free at 20 months of 
age; the efficacy results were encouraging. It appeared that 
the children treated with the proposed therapeutic dose 
early in age (in the first month of life) and early in the 
disease course achieved more advanced motor milestones 
and did so more rapidly, emphasizing the need for newborn 
screening in SMA1 when treatments become available 
[41]. Overall, the data obtained with the gene therapy trial 
also suggest that in SMA type 1, treatment within 3 months 
is associated with significant motor milestone  response, 
but to have a greater clinical effect (i.e., to achieve inde- 
pendent walking) treatment within 1 month, or even within 
fewer weeks, is likely needed. 
  
 
Discussion 
 
Pathophysiology of the Disease and the Therapeutic 
Window 
 
Understanding what limits the therapeutic time window may be 
crucial to implementing efficient combinational therapeutics, 
which can increase the efficacy of SMN-dependent therapies. 
SMA, in its most severe forms, presents a clinical onset during 
the perinatal period that is a crucial time of neuromuscular 
development and maturation. Thus, key aspects in SMA path- 
ogenesis involve defective motor neuron development and pro- 
gressive loss of motor neurons. It is not clear whether there exist 
elements that limit this therapeutic time window during very 
early stages in disease, and if so, what these elements are. One 
hypothesis is that this time can correlate with irreversible motor 
neuron damage, beyond which even restoring SMN levels is 
not sufficient for their survival. This time point can also reflect a 
developmental requirement for SMN within the neuromuscular 
system, in particular in severe types of SMA, which may limit 
the efficacy of SMN replacement therapies. 
Some studies have revealed that motor neuron and synapse 
defects are present during fetal development, supporting a role 
for SMN in motor neuron development [16]. This can be more 
prominent in the case of severe reduction of SMN. However, 
these developmental aspects might be compatible with a full 
functional rescue, as indirectly proven by the preliminary re- 
sults of a full rescue of subjects treated during the presymp- 
tomatic stage (Nurture trial). Indeed, this study also suggested 
that early rescue of SMN level can halt the motor neuron 
degeneration. The two elements to reduce the impact of the 
therapeutic window for an SMN-dependent strategy to pre- 
serve motor neurons are represented by increasing the efficacy 
and biodistribution of gene therapy/ASO treatments for SMA 
to allow a maximal and rapid rescue of SMN and by imple- 
ment SMA neonatal genetic screening for presymptomatic 
treatments. 
The first sign of motor neuron distress is axonal withdrawal 
and neuromuscular junction impairment. When the soma of 
the motor neuron is healed through the increase in SMN ex- 
pression, it can regrow the axon and restore a proper neuro- 
muscular junction connection. 
However, nerves that have sustained injuries closer to their 
soma are less likely to survive and regenerate, and chronic 
denervation is exacerbated by the slow axon regeneration rate 
of ~ 1 mm/day and axon misdirection, where axons reconnect 
to the wrong target [42]. Strategies that promote proper axon 
regrowth are important but still underdeveloped in motor neu- 
ron diseases. 
Proper development and organization at the NMJ are nec- 
essary for effective neuromuscular transmission. However, 
SMN reduction may affect the axon innervation and the 
organization/maturity of the acetylcholine receptor, resulting 
in the impairment of neuromuscular transmission. It has been 
hypothesized that an alteration to normal developmental pro- 
cesses could directly contribute to NMJ pathogenesis in SMA 
patients. This led to the hypothesis that reduced levels of SMN 
could alter the development of some, or all, cells contributing 
to the NMJ, thus causing this structure to be selectively vul- 
nerable to subsequent degeneration during disease. 
In theory, injured peripheral nerves and skeletal muscles 
have a natural ability for tissue regeneration [43], and regen- 
eration of functional NMJs occurs after NMJ injury [44]; thus, 
when SMN is restored, NMJ and muscles can recover. 
However, this process is very delicate. In fact, the alteration 
of regenerated NMJs formed at both original synaptic sites 
and new synaptic areas can be associated with permanent 
neurological deficiency and long-term skeletal muscle con- 
tractile dysfunction. It is unknown whether these aspects can 
influence the recovery of SMA after treatment. NMJ can be an 
important target for expanding the therapeutic window. 
Restoring SMN protein in SMA mice during early postnatal 
life resulted in the accumulation of presynaptic and postsyn- 
aptic abnormalities of the neuromuscular junction of mutant 
mice, which eventually precluded any benefit that could be 
obtained from restoring SMN [22]. Progressively fewer de- 
fects were observed the earlier the protein was restored. 
Future therapeutic strategies should be focused on extend- 
ing the therapeutic time window, in particular by stabilizing 
the neuromuscular system for a longer period. This would 
allow for a greater therapeutic benefit from SMN-targeted 
therapies (such as oligonucleotides or gene therapy), and/or 
would independently act to stabilize the neuromuscular sys- 
tem beyond the time window that currently is present for 
SMN-targeted therapies. In this sense, the investigator com- 
pound Olesoxime acts as neuro-protectant on motor neurons, 
preventing excessive permeability of the mitochondrial mem- 
brane under stress conditions [45]. 
Muscular activators such as CK-2127107 (CK-107) can 
improve muscle function of SMA patients by enhancing mus- 
cle contractions. CK-107 is a fast skeletal muscle troponin 
activator and is intended to slow the rate of calcium release 
from the regulatory troponin complex of fast skeletal muscle 
fibers and thus improve muscle function. While this type of 
strategy did not require a specific time window, being SMN- 
independent, it required at least some degree of muscle 
functionality. 
It is important to identify novel molecular with therapeutic 
target independent from SMN and acting synergistically on 
therapies that restore the protein synthesis. 
 
 
Conclusions and Perspectives 
 
SMA is a neurodegenerative disease in which MN degenera- 
tion and loss are continuous and progressive from birth. The 
 
 
 
 
general assumption is that the sooner the therapy is started, the 
greater the advantage will be. A precise therapeutic window 
has not been defined. In SMA type 1, according to the exper- 
imental data obtained so far, the therapeutic window can be 
hypothesized to be, optimally, within 1 month of age or even 
within few weeks after birth (ideally 1 week), sufficient to 
have a motor function response within 3 months of age and, 
well suboptimally, within 6 months (Fig. 2). The therapeutic 
timeframe for SMA type 2 to 4 is undefined. All patients, until 
now, enrolled in clinical trials with oligonucleotides and gene 
therapy were children under the age of 12 years. 
Therapy should be applied when MNs are still alive and 
should aim to preserve SMN function during cell development 
and during elaboration of neuromuscular synapses [22, 49]. 
The clinically detectable motor impairment can be more 
prominent than the number of soma of motor neurons lost 
since instability of NMJ or distal axonal loss is sufficient to 
result in muscle weakness. Thus, it can be hypothesized that in 
the early symptomatic stage, even if hyposthenia is evident, a 
prompt restoration of SMN level could allow motor neurons 
to regrow these axons and recreate their connections with 
muscles. 
 
 
 
Fig. 2 Therapeutic window in humans. a For patients with SMA type 1, 
the mortality rate is 25 to 50% by 8 months and 75 to 90% by 12 months 
of age (Niranjan et al. [46]; Bach et al. [47]; Finkel et al. [48]). Gray 
represents the motor milestone for healthy subjects. b The violet, red, 
and green curves represent the CHOP INTEND, CMAP, and MUNE 
trends, respectively, in SMA type I patients. Patients treated with SMN 
rescue therapy at less than 1 month of age developed motor performance 
comparable to that of healthy subjects. According to the residual motor 
unit estimates with the CMAP and MUNE motor performances and the 
amelioration obtained in clinical trials so far, the best period for 
therapeutic intervention was within 1 month (pink area), and ideally 
within 1 week after birth (red net area). Additionally, when the 
treatment was administered in the following months, a gain in motor 
performances was observed to be higher within 3 months (orange area) 
and milder later in life (yellow area) 
  
 
Experiments conducted in different animal models of the 
disease showed different timing for intervention of SMN pro- 
tein in the development and maintenance of MNs, in particular 
their distal compartment (axon and NMJ). The requirement of 
SMN protein during the embryonic and early postnatal period 
is consistent with the early age of onset of SMA in human 
patients. 
SMN-enhancing agents were most effective in halting the 
progression of SMA if administered early on during the dis- 
ease before complete maturation of neuromuscular synapses 
has been reached. Furthermore, tapering of drug concentra- 
tions and possible subsequent reintroduction should be con- 
sidered once the disease has been stabilized. However, it 
seems that SMN represents a maintenance factor for NMJ 
structure and is invoked at specific moments of adult life. 
Thus, SMN can also be required during muscle regeneration 
in adulthood. 
Shortly after birth, the blood–brain barrier is relatively per- 
meable and more easily crossed by therapies; moreover, the 
probability that younger patients will present immune re- 
sponse against viral vector is lower. Although a specific win- 
dow of opportunity has not yet been defined in humans, it 
seems reasonable to postulate that there is a short critical pe- 
riod after which therapeutic advantages appear to wane. 
Moreover, in the severe SMA phenotype, this crucial window 
is narrow and short-lived. 
The maturation processes and the modifications of CNS 
structures (BBB, neurons, and extracellular matrix) after birth 
and during infancy can have an impact on the drug (AAV and 
oligonucleotides) biodistribution and, consequently, on the 
therapeutic window. The distribution of the drug through the 
tissues to the target cells could be implemented using molec- 
ular strategies as peptide conjugation for oligonucleotides. 
SMN restoration may not only arrest but also reverse an overt 
disease phenotype, with important therapeutic implications 
for human beings. There is evidence that earlier intervention 
is more effective at modulating disease severity than interven- 
tion at later stages, resulting in longer survival and better mo- 
tor performance, although there are mild benefits even when 
SMN protein is restored at relatively later stages. Currently, 
ongoing clinical trials are based on the use of gene therapy 
with AAV9 to deliver the SMN1 gene and on the use mole- 
cules that modulate SMN2 splicing. So far, data provided have 
shown promising results. The rapidity and the efficacy with 
which results are achieved in clinical trials might accelerate 
the procedures for approval by healthcare organizations of the 
experimental drug as therapy for SMA. 
Looking at the results presented so far by the scientists 
promoting clinical trials with antisense oligonucleotides 
(Nusinersen) and gene therapy (AAV9-SMN), patients with 
SMA type 1 treated at an earlier age achieved the best out- 
come measure results (Fig. 2). A few studies showed that soon 
after birth, patients with SMA type 1 presented low CMAP 
and MUNE levels that rapidly decreased in the first few 
months of life [10, 12, 30, 50]. It seems reasonable to hypoth- 
esize that the first 2 to 3 months are the limit within which the 
therapy administration can potentially impact the SMA1 dis- 
ease phenotype. Nevertheless, it seems that the treatment is 
more effective when given at a higher dose and at an earlier 
time point. 
Prompt administration of SMN-restoring agents (within 
days from diagnosis), together with routine newborn screen- 
ing for SMA, will optimize results in clinical trials. Positive 
results and the deeper understanding of the functions of new 
molecules suggest that these molecules could also be applica- 
ble for other genetic diseases. In particular, gene therapy 
would be ideal for treatment of spinal muscular atrophy with 
respiratory distress type 1 (SMARD1); SMARD1 is a neuro- 
degenerative disease caused by mutations in the IGHMBP2 
gene, which begins in childhood and leads to inexorable mus- 
cular atrophy. Encouraging results have been obtained in pre- 
clinical studies for this disorder; in fact, the phenotype of a 
SMARD1 mouse model was rescued after systemic injection 
of an AAV9 construct encoding the wild-type IGHMBP2 to 
replace the defective gene [51]. 
For both SMA and SMARD1, early treatment is essential 
despite the fact that the therapeutic window for both of these 
diseases in humans has yet to be established. The different 
molecules currently under evaluation are being shown to be 
excellent therapeutic possibilities to treat SMA. It becomes 
essential to realize and finalize the clinical trials in order to 
compare the safety and efficacy profiles of each molecule to 
the others and optimize their use in accordance to the patient 
clinical features. The timing of administration is of crucial 
importance and is closely linked to the time of diagnosis. 
Time is motor neuron in infantile SMA, a finding that reflects 
the neurological urgency of treatment. Therefore, in parallel 
with the optimization of therapy, it is necessary to implement a 
neonatal screening program with the future prospect of possi- 
ble early intervention or prenatal diagnosis. 
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